Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05160597 · ClinicalTrials.gov registry record · Early Phase 1

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

A Early Phase 1 study of Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Active
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05160597 is a Early Phase 1 study of Prostate Carcinoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05160597, a Early Phase 1 study of Prostate Carcinoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomography/computed tomography (PET/CT) scan works in diagnosing prostate cancer in men with a prior negative or inconclusive prostate biopsy. PSMA is a protein that is found on the surface of prostate cancer cells. 68Ga-PSMA-11 is made up of a substance that binds to PSMA on tumor cells, linked with a radioactive substance that can then be seen on imaging scans such as PET/CT. 68Ga-PSMA-11 PET/CT-guided biopsy may help improve the detection rate of prostate cancer. This may help reduce over-diagnosis and over-treatment in men with low-risk prostate cancer and under-treatment in men with high-risk prostate cancer.

Conditions Studied

Prostate Carcinoma

Interventions

  • PROCEDURE Biopsy of Prostate
  • OTHER Gallium Ga 68 Gozetotide
  • PROCEDURE Transrectal Ultrasonography Guided Biopsy

Study Locations (1)

California

  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-01-13
Est. Completion 2027-01-07
Phase Early Phase 1

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05160597

The ClinicalTrials.gov registry entry for NCT05160597 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biopsy of Prostate is the first listed.

NCT05160597 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05160597 about?

NCT05160597 is a clinical study titled "Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy". This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomography/computed tomography (PET/CT) scan works in diagnosing prostate cancer in men with a prior negative or inconclusive p...

What is the current status of trial NCT05160597?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2022-01-13. Estimated completion is 2027-01-07.

What conditions does trial NCT05160597 study?

This clinical trial studies the following conditions: Prostate Carcinoma.

What interventions are being tested in trial NCT05160597?

The interventions under investigation include: Biopsy of Prostate (PROCEDURE), Gallium Ga 68 Gozetotide (OTHER), Transrectal Ultrasonography Guided Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT05160597?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05160597 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.